279
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Self-reported treatment adherence among psychiatric in- and outpatients

, , , , , , , , & show all
Pages 526-533 | Received 06 Mar 2018, Accepted 16 Oct 2018, Published online: 16 Nov 2018

References

  • Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4:269–286.
  • Thompson L, McCabe R. The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review. BMC Psychiatry. 2012;12:87.
  • Joosten EA, DeFuentes-Merillas L, de Weert GH, et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77:219–226.
  • Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.
  • Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164–172. Mar
  • Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003;64: 3–9.
  • Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886–891. Aug
  • Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005;7 Suppl 5: 24–31.
  • Meehan J, Kapur N, Hunt IM, et al. Suicide in mental health in-patients and within 3 months of discharge. National clinical survey. Br J Psychiatry. 2006;188:129–134. Feb
  • Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–699. Apr
  • Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805–811. Jun
  • Hearnshaw H, Lindenmeyer A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabet Med. 2006;23:720–728. Jul
  • Haynes RB, Sackett DL. Compliance with therapeutic regimens. Baltimore (MD): Johns Hopkins University Press; 1976.
  • Sajatovic M, Velligan DI, Weiden PJ, et al. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010;69:591–599.
  • Velligan DI, Weiden PJ, Sajatovic M, et al. Expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70: 1–46. quiz 47-8.
  • Murru A, Pacchiarotti I, Amann BL, et al. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord. 2013;151:1003–1008. Dec
  • Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013;149:247–252. Jul
  • Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25:1158–1166. Aug
  • Gibson S, Brand SL, Burt S, et al. Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry. 2013; 13:153.
  • Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13 Suppl 3:S69–S75. Sep
  • Holma IA, Holma KM, Melartin TK, et al. Treatment attitudes and adherence of psychiatric patients with major depressive disorder: a five-year prospective study. J Affect Disord. 2010;127:102–112. Dec
  • Arvilommi P, Suominen K, Mantere O, et al. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study . J Affect Disord. 2014;155:110–117. Feb
  • Gray R, Bressington D, Ivanecka A, et al. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16:90.
  • Coodin S, Staley D, Cortens B, et al. Patient factors associated with missed appointments in persons with schizophrenia. Can J Psychiatry. 2004;49:145–148. Feb
  • Aaltonen K, Näätänen P, Heikkinen M, et al. Differences and similarities of risk factors for suicidal ideation and attempts among patients with depressive or bipolar disorders. J Affect Disord. 2016; 193:318–330.
  • Karpov B, Joffe G, Aaltonen K, et al. Anxiety symptoms in a major mood and schizophrenia spectrum disorders. Eur Psychiatry. 2016; 37:1–7.
  • World Health Organization. International classification of disease. 10th ed. Geneva: WHO; 1992.
  • Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–571.
  • Norman SB, Cissell SH, Means-Christensen AJ, et al. Development and validation of an Overall Anxiety Severity and Impairment Scale (OASIS). Depress Anxiety. 2006;23:245–249.
  • Zanarini MC, Vujanovic AA, Parachini EA, et al. A screening measure for BPD: the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD). J Pers Disord. 2003; 17:568–573.
  • Babor TF, Saunders J, Grant M. AUDIT: the alcohol use disorder identification test: guidelines for use in primary health care. Geneva (Switzerland): World Health Organization; 1992.
  • IBM Corp. IBM SPSS Statistics for Windows, Version 22.0. Armonk (NY): IBM Corp; 2013.
  • Bø B, Ottesen ØH, Gjestad R, et al. Patient satisfaction after acute admission for psychosis. Nord J Psychiatry. 2016;70:321–328. Jul
  • Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry. 2004;65:1211–1218. Sep
  • De Las Cuevas C, Peñate W. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. Hum Psychopharmacol Clin Exp. 2015;30:377–383. Sep
  • Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, et al. Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics. Int J Neuropsychopharmacol. 2014;18:pyu091.
  • Sajatovic M, Levin JB, Sams J, et al. Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. Bipolar Disord. 2015;17:653–661. Sep
  • Nielsen RE, Lindström E, Nielsen J, et al. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22:747–750. Oct
  • Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30:169–175. Apr
  • Grinshpoon A, Lerner Y, Hornik-Lurie T, et al. Post-discharge contact with mental health clinics and psychiatric readmission: a 6-month follow-up study. Isr J Psychiatry Relat Sci. 2011;48:262–267.
  • Saxena S, Thornicroft G, Knapp M, et al. Resources for mental health: scarcity, inequity, and inefficiency. Lancet. 2007;370:878–889. Sep 8
  • Malowney M, Keltz S, Fischer D, et al. Availability of outpatient care from psychiatrists: a simulated-patient study in three U.S. cities. Psychiatr Serv. 2015;66:94–96. Jan 1
  • Fung KM, Tsang HW, Corrigan PW. Self-stigma of people with schizophrenia as predictor of their adherence to psychosocial treatment. Psychiatr Rehabil J. 2008;32:95–104. Fall
  • Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24:143–155.
  • Keyes KM, Hatzenbuehler ML, McLaughlin KA, et al. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol. 2010;172:1364–1372.
  • Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–341.
  • Wahlbeck K, Westman J, Nordentoft M, et al. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br J Psychiatry. 2011;199:453–458.
  • Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.
  • Yuodelis-Flores C, Ries RK. Addiction and suicide: a review. Am J Addict. 2015;24:98–104.
  • Chien WT, Mui JH, Cheung EF, et al. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. Trials. 2015;16:270.
  • Melartin TK, Rytsala HJ, Leskela US, et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry. 2002;63:126–134.
  • Mantere O, Suominen K, Leppämäki S, et al. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord. 2004;6:395–405.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.